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Scope: Intake of wholegrain has been linked with reduced chronic disease mortality, with oat 
intake particularly notable for lowering blood cholesterol and glycemia. To better understand 
the complex nutrient profile of oats, we studied the absorption, distribution, metabolism and 
excretion (ADME) of phenolic acids and avenanthramides after ingestion of oats in humans. 
Methods and results: After a 2d (poly)phenol-low diet, 7 healthy men provided urine 12h 
before, and 48h after, consuming 60g oat bran (7.8µmol avenanthramides, 139.2µmol phenolic 
acids) or a phenolic-low (traces of phenolics) control in a crossover design. Analysis by UPLC-
MS/MS indicated that oat bran intake resulted in an elevation in urinary excretion of 33 
phenolics relative to control, suggesting that they are oat bran-derived. Mean excretion levels 
were elevated between 0-2 and 4-8h, following oat bran intake, and amounted to a total of 
34.8±7.2µmol total excretion (mean recovery: 23.6±4.9%), relative to control. The 
predominant metabolites included: vanillic acid, 4- and 3-hydroxyhippuric acids and sulfate-
conjugates of benzoic and ferulic acids, which accounted for two thirds of total excretion. 
Conclusion: Oat bran phenolics follow a relatively rapid ADME, with 33 metabolites excreted 





Increasing the daily intake of wholegrain cereals by 90g has been associated with reduction 
mortality from cardiovascular disease by 27%, total cancer by 15%, respiratory disease by 
22%, diabetes by 51% and infectious diseases by 26%, as indicated by recent meta-analysis of 
45 prospective studies [1]. Human intervention studies have to date largely focused on 
wholegrain oats (Avena sativa), with meta-analyses establishing that regular oat intake lowers 
blood cholesterol [2, 3] and improves insulin sensitivity and post-prandial glycemic control 
[4]. Although oats only account for 1% of world grain production, they, unlike more widely 
consumed grains, are almost exclusively consumed as wholegrains and therefore a rich dietary 
source of high quality proteins, minerals, vitamins, soluble β-glucan fiber and phenolic 
compounds (i.e. phenolic acids and avenanthramides), all of which are concentrated in the 
outer bran layers [5]. 
β-glucan is, at least in part, responsible for the health benefits of oats [2-4], while there is 
limited in vitro evidence that avenanthramides [6] and phenolic acids [7] also may also 
promote beneficial cardiovascular physiology. Phenolic acid intake in Europe is on average 
605 mg/d, with the main dietary sources being coffee (75%), fruits (5.6%) and wholegrain 
products (5.5%) [8]. Wholegrain is the richest dietary source of ferulic acid, which has a mean 
intake of 38 mg/d in Europe [8], although a number of other phenolic acids and phenolic 
alkaloids, notably the avananthramides, are present in oats, either in the ‘free form’, as soluble 
conjugates, or as insoluble bound forms (including ester-linked to fiber) [9]. Understanding 
the absorption, distribution, metabolism and excretion (ADME) of oat phenolic compounds 
following the dietary intake of whole oats or oat bran is a key prerequisite for determining 
which phenolic metabolites may mediate the health benefits of oats.  
 
 
Previous data using oat phenolic extracts or wheat have indicated that phenolics transfer to the 
circulation following intake [10, 11], whilst limited data exist for the ADME of phenolics and 
other bioactive components from whole oats or oat bran. Notably, the intake of 150 mg of 
avananthramides (highly concentrated oat extract), led to detection of avenanthramides 2c, 2f 
and 2p at nanomolar concentrations in plasma between 0.25 and 5h, peaking at 2h [11]. While 
this study did not examine metabolism, data from studies in animals suggest that 
avenathramide 2c is metabolized to avenanthramide 2f, dihydroavenanthramide 2f and 2c, four 
hydroxycinnamic acids, and 5-hydroxyanthranilic acid following oral intake [12]. 
Furthermore, intake of 94 g wholegrain wheat bread, containing 87 mg of ferulic acid or 
aleurone-enriched white bread led to the appearance of ferulic acid-sulfate, dihydroferulic-
sulfate, hippuric acid and two hydroxyhippuric acids in plasma, with the former two reaching 
peak plasma concentrations of 84 nM and 9 nM at 1 and 7 h after intake, respectively [10], 
along with 12 other phenolic acid metabolites in 48h urine, suggesting that ferulic acid is 
subject to extensive metabolism and that some fiber-linked ferulic acid is released later during 
transit through the gastrointestinal track through action of the microbiota [10]. 
The aim of our study was to examine the ADME of avenanthramides and phenolic acids 
following intake of 60g oat bran. Specifically, the study focused on three objectives; 1) to 
establish peak urinary excretion intervals of phenolic acids and avenanthramides; 2) to 
determine the temporal nature of oat phenolic release from the bound state in the 
gastrointestinal tract; and 3), to identify and quantify the range of phenolic metabolites derived 
from the oat phenolics using comprehensive UPLC-MS/MS methods. 
2 MATERIALS AND METHODS 
2.1 Chemicals and reagents 
 
 
Avenanthramide 2c, avenanthramide 2f, avenanthramide 2p, 2,4-dihydroxy benzoic acid, p-
coumaric acid, caffeic acid, isoferulic acid, syringic acid, salicylic acid, o-coumaric acid, 
vanillic acid, syringaldehyde, ferulic acid, sinapic acid, 4-hydroxybenzaldehyde, 4-
hydroxybenzoic acid, vanillin, protocatechuic acid, isovanillic acid, gallic acid, homovanillic 
acid, hippuric acid, dihydroferulic acid, dihydrocaffeic acid, 4-hydroxyphenylacetic acid and 
2-hydroxyhippuric acid were obtained from Sigma-Aldrich (see Supporting Information Table 
1 for IUPAC names). Dihydroferulic acid-4-O-glucuronide, isoferulic acid-3-O-sulfate, ferulic 
acid-4-O-glucuronide, dihydroxybenzoic acid-3-O-glucuronide and 5-hydroxyanthranilic acid 
were obtained from Toronto Research Chemicals Inc. 4-hydroxyhippuric acid and 3-
hydroxyhippuric acid were purchased from Enamine (see Supporting Information Table 1 for 
IUPAC names). All solvents were HPLC grade and were obtained from Sigma-Aldrich or 
Fisher Scientific. While we acknowledge that avenanthramides are phenolic alkaloids, the 
terms phenolics is used throughout the paper to include both avenanthramides and phenolic 
acids. 
 
2.2 Extraction and analysis of oat bran phenolics 
Soluble and bound phenolic fractions were extracted from oats using an established method 
[13], with addition of hexane defatting steps adapted from [14] and preservation of phenolics 
during alkali hydrolysis using ascorbate and EDTA adapted from [15]. Phenolic acids and 
avenanthramides were separated using an Agilent 1100 series HPLC equipped with a Kinetex 
biphenyl column (100 Å 250x4.6 mm, 5µm; Phenomenex) with a SecurityGuard ultra biphenyl 
cartridge (Phenomenex). Sample injection volume was 20 μL, the flow rate 1 mL/min and 
mobile phases consisted of 0.1% formic acid (v/v) in water (solvent A) and 0.1% formic acid 
(v/v) in methanol (solvent B). The solvent gradient consisted of 5% B at 0 min, 25% B at 20 
 
 
min, 26% B at 25 min, 35% B at 30 min, 36% B at 40 min, 70% B at 53 min, 95% B at 56 min, 
95% B at 61 min, 5% B at 62 min, 5% B at 65 min. The absorbance was recorded at 254, 280 
and 320nm and quantification was based on 12 point linear calibration curves (mean R2 > 
0.994) and as a ratio to the internal standard (i.e. 3,5-dichloro-4-hydroxybenzoic acid) to 
account for losses during extraction. 
 
2.3 Study design 
Seven healthy men aged 25-62 years were recruited from the local community. Exclusion 
criteria were as follows: recent (last 3 months) use of antibiotics, flu vaccination or dietary 
supplements. All participants gave written informed consent prior to study commencement and 
the study was performed at the Hugh Sinclair Unit of Human Nutrition, University of Reading 
(UK) between July 2014 and September 2014 and was approved by the University of Reading 
Research Ethics Committee (Reference number: 31/15), followed the principles of the 
Declaration of Helsinki and was registered on ClinicalTrials.gov under NCT02574039. 
The study was designed as a non-blinded, randomized, controlled trial, where participants 
attended two experimental visits that were identical with the exception of the two study meals: 
1) Test intervention consisting of 60 g oat bran porridge, 200 ml semi-skimmed milk and 100 
ml water, microwaved (2min); or 2) a control consisting of two slices of white bread, 14g 
butter, golden syrup, one boiled egg and 200 ml semi-skimmed milk; given in random order. 
Participants arrived at the Nutrition Unit at 8am or 9am to consume the study meal within 10 
min. Urine was collected at 11 specific intervals relative to study meal consumption: -12h to 
0h (i.e. baseline), 0h to 2h, 2h to 4h, 4h to 6h, 6h to 8h, 8h to 12h, 12h to 24h, 24h to 28h, 28h 
to 32h, 32h to 36h and 36h to 48h (see Figure 1). Collected urine was kept on ice pack and 
immediately following extraction, aliquots were stored at -80°C with and without 5% formic 
 
 
acid acidification. During the 48h urine collection period, participants consumed a low-
phenolic meals provided to them (lunch: a white bread cheese sandwich and toffee yoghurt; 
dinner: macaroni cheese pasta, white bread roll and crème brulée; breakfast: white toast with 
butter and golden syrup, a boiled egg and glass of milk), whilst drinking water ad libitum. Prior 
to each experimental visit, participants followed a diet low in (poly)phenols for 48h (i.e. no 
fruits, vegetables, wholegrains, pulses, spices, herbs, nuts, seeds, chocolate, tea and coffee), 
and attended an overnight fast after having consumed a low-(poly)phenol dinner (a cheese pasta 
bake, white bread roll and crème brulée). Compliance to the dietary restrictions was assessed 
using food intake diaries and questionnaires. One volunteer was excluded from the final 
dataset, due to non-compliance to the dietary restrictions (i.e. volunteer reported intake of 
(poly)phenol-rich foods and baseline and post-control urine contained high levels of 
phenolics). 
 
2.4 Solid phase extraction 
Phenolic acids were extracted from urine using a validated method [16] with minor 
modifications. Briefly, 1 mL of urine was spiked with an internal standard (i.e. 3,5-dichloro-4-
hydroxybenzoic acid) and subsequently extracted using solid phase extraction cartridges 
(Strata-X columns 500mg/6mL; Phenomenex). These were washed with 12 mL of 0.1/99.9 v/v 
hydrochloric acid/water, dried for 30 min under vacuum, soaked in 0.1/99.9 v/v hydrochloric 
acid/methanol for 10 min and eluted into glass vials with 7 mL 0.1/99.9 v/v hydrochloric 
acid/methanol. Samples were evaporated to complete dryness under speedvac at room 
temperature. The dried samples were resuspended in 250 μL of mobile phase (0.1/5/94.9, v/v/v, 
formic acid/methanol/water) by 30s vortexing, 15min ultrasound sonicating and 1h shaking. 
Samples were stored at -80°C until analysis. For phenolic acids and metabolites the method 
 
 
has a mean ± SD extraction efficiency of 88.3 ± 17.8% [16], while we established extraction 
efficiencies of 102%, 97% and 57% for avenanthramide A, B and C, respectively. 
2.5 UPLC-MS/MS analysis 
The UPLC-electrospray ionisation-MS/MS system consisted of an Aquity UPLC Hclass 
(Waters) coupled to a Xevo TQ-S micro electrospray ionisation mass spectrometer (Waters) 
operated using MassLynx software (V4.1, Waters Inc, USA). Compound separation was 
achieved using an Aquity UPLC HSS T3 1.8µm column (2.1 x 100mm) attached to a Van 
guard pre-column of the same material and pore size, maintained at 45°C with a flow of 0.65 
mL/min and a sample injection volume of 2 μL. The mobile phase consisted of 0.1/99.9 v/v 
formic acid/water (A) and 0.1/99.9 v/v formic acid/acetonitrile (B); and a mobile phase gradient 
consisting of: 1% B at 0 min, 1% B at 1 min, 30 % B at 10 min, 95 % B at 12 min, 95% B at 
13 min, 1% B at 13.10 min, 1% B at 16 min. A scheduled multiple reaction monitoring (sMRM) 
method was developed by syringe infusion of 34 analytical standards (see section Chemicals 
and Reagents and Supporting Information Table 1) to determine sMRM transitions, optimal 
sMRM modes (i.e. negative or positive) and collision energies (Supporting Information Table 
2). 
Regarding phase II metabolites, while four authentic standards were used for the sMRM 
method (i.e. dihydroferulic acid-4-O-glucuronide, isoferulic acid-3-O-sulfate, ferulic acid-4-
O-glucuronide and dihydroxybenzoic acid-3-O-glucuronide), further putative glucuronide or 
sulfate conjugated phenolic acid metabolites and feruloyl glycine were added to the sMRM 
method, even though analytical standards were not commercially available. For these, retention 
times and sMRM transitions were tentatively identified by injecting a pooled extract of urine 
(i.e. using urine collected after oat bran intake from all n=7 participants and during all 10 post-
intake time intervals). sMRM transitions were taken from the literature [17-19] or derived from 
 
 
the fragmentation pattern of the phenolic acid aglycones by adding the m/z of glucuronide (i.e. 
176) or sulfate (i.e. 80) to the precursor ion and including the appropriate MS/MS fragment. 
Furthermore, 113 m/z, a common fragment of glucuronic acid, was added as an MS/MS 
fragment for glucuronide conjugates [19]. Collision energies were optimized to a limited extent 
by injecting the pooled urine extract three times at collision energies -11, -17 and -21 and the 
best one was selected for each sMRM transition. In the final sMRM, a total of 84 potential 
compounds were targeted and statistical comparison between the oat and control intervention 
was used to identify those which are oat-derived phenolics. 
Quantification was established using the most intense sMRM transition and 11-14 point 
calibration curves of analytical standards (Supporting Information Table 2). Where pure 
standards were not available, quantification was conducted relative to standard curves of 
compounds with similar structures (e.g. the calibration curve of isoferulic acid-3-O-sulfate was 
used to quantify all tentatively identified sulfate metabolites). The limit of detection was 
established for each compound as the concentration of a peak with a signal to noise ratio of 3. 
A blank and quality control were run every 10 injections and the quality control indicated a 
between-run coefficient of variation of 10%.  
Sample acidification using 5% formic acid did not significantly affect phenolic compound peak 
areas (established in n=3 volunteers; data not shown) and therefore non-acidified urine was 
used for the complete analysis. 
 
2.6 Statistical analysis 
A two-factor repeated-measurement linear mixed model was fitted to analyze hourly urinary 
excretion data. The model included participants nested within time as a random effect and 
baseline hourly urinary excretion, intervention, time and interaction as fixed effects. When the 
 
 
model showed a significant interaction effect, post-hoc analysis with Tukey-Kramer 
adjustment was performed. Data are presented as means ± SEMs. P-values of <0.05 were 
considered statistically significant, and statistical analysis was performed by using R 
programming language version 3.1.2 (R Development Core Team, 2014). 
 
3 RESULTS 
3.1 Phenolic composition of the oat bran intervention 
Twelve 12 phenolic compounds were detected in the oat bran used for the trial, with eight 
phenolic acids being present in both soluble and bound fractions, three avenanthramides only 
present in the soluble fraction and vanillin only in the bound fraction (Table 1). The 
intervention diet (60g oat bran) contained 28.6mg total phenolics (24% in the soluble fraction), 
with ferulic acid being the predominant phenolic acid (16.8mg) followed by p-coumaric acid 
(3.3mg) and the three avenanthramides collectively amounting to 2.5mg. Although the control 
meal and all other meals consumed during the 48h study periods were not analyzed, they 
consisted of white wheat bread and pasta and would therefore be expected to contain only low 
amounts of phenolic acids [20]. 
 
3.2 Identification of oat derived phenolic compounds in urine 
A wide range of phenolic compounds were detected in urine at baseline and after the control 
meal intake (Supporting Information Table 3). However, the hourly excretion of 33 individual 
phenolic compounds was elevated following intake of oat bran compared to the control 
intervention (significant mixed model P-value of intervention and/or time*intervention; 
Supporting Information Table 3), suggesting that they are derived from the ingested oat bran. 
 
 
These phenolics were identified as two avenanthramides and 31 phenolic acids (11 aglycones, 
four glycine conjugates, 10 sulfate conjugates and eight glucuronide conjugates; Supporting 
Information Table 2). Excretion of hippuric acid, the dominant phenolic acid in human urine, 
and ferulic acid aglycone were not statistically higher after the oat bran intervention relative to 
the control and were thus not identified as oat-derived metabolites (mixed model 
time*intervention interaction P-values: 0.36 and 0.06, respectively; Supporting Information 
Table 3). 
3.3 Hourly urinary excretion of oat phenolic compounds 
At baseline, the mean hourly excretion of the total excretion of 33 phenolic compounds prior 
to oat bran and control interventions was 2.5±0.6 µmol/h and 1.9±0.4 µmol/h, respectively 
(Figure 2). Following intervention, the total hourly phenolic excretion significantly increased 
at 0-2h (oat: 9.5±0.6 µmol/h, control: 1.9±0.4 µmol/h; post-hoc P-value <0.0001), returned to 
a similar level as control at 2-4h (oat: 4.8±0.9 µmol/h, control: 4.0±1.2µmol/h; post-hoc P-
value P-value >0.05) and peaked again between the 4-6 h period (oat: 8.8±1.9µmol/h, control: 
4.0±0.7µmol/h; post-hoc P-value < 0.05) and 6-8h (oat: 13.0±1.2µmol/h, control: 
7.5±0.6µmol/h; post-hoc P-value < 0.01) before returning to a similar level to the control 
intervention from 8 to 48h (mixed model P-values: time < 0.0001, intervention <0.01 and 
time*intervention interaction <0.0001; Figure 2). Figure 3 shows the oat-bran induced increase 
in excretion of the individual 33 oat-derived phenolics proportional to the total excretion at 0-
2h, 4-6h and 6-8h, relative to control. Vanillic acid, 4-hydroxyhippuric acid, 3-hydroxyhippuric 
acid, benzoic acid-sulfate and ferulic acid-sulfate were the predominant oat bran-derived 
phenolics excreted, accounting for more than two thirds of the total excretion (i.e. 20.3%, 
16.1%, 14.3%, 9.8% and 7.3%, respectively). (Iso)ferulic acid-sulfate was predominant early 
during the early 0-2h peak, vanillic acid was almost exclusively excreted during the late 4-8h 
period, whilst excretion of hydroxyhippuric acids and benzoic acid-sulfate was biphasic, with 
 
 
early and late peaks (Figure 3). Ferulic acid, p-coumaric acid and avenanthramides 2p and 2f 
(i.e. the most abundant phenolic compounds in oats) accounted only for small percentages of 
the total excreted phenolics (i.e. 0.18%, 0.03%, 0.02% and <0.01%, respectively; Figure 3), 
suggesting that they are subject to extensive metabolism. 
The mean absolute urinary excretion of the 33 oat-derived phenolics from 0-8h was 
72.3±0.8µmol after consumption of oat bran and 37.5±4.5µmol after the control intervention 
(Table 2). Hence, on average 23.6±4.9% of the ingested dose (i.e. 147µmol phenolics/60g oat 
bran; Table 1) was recovered in the 0-8h urine and there was large inter-individual variability 
in absorption that ranged from 4.8% to 41.6% (Table 2). The mean percentage recovery of 
metabolites was lowest for the avenanthramides (range: 0-0.3%), intermediate for 
hydroxycinnamic acids (6.3-10.6%) and highest for hydroxybenzoic acids (14.6-159.2%). 
 
4 DISCUSSION 
The present controlled trial examined ADME of phenolic metabolites following intake of oat 
bran over a 48h timeframe. Oat bran intake resulted in elevated urinary excretion of 33 phenolic 
compounds at 0-2h and 4-8h, with sulfate or glycine conjugated benzoic acids being the major 
metabolites together with ferulic acid sulfate, and the total amounts of phenolic compounds 
recovered in urine amounting to 23.6±4.9% of the ingested phenolic dose. These results suggest 
that a high proportion of oat phenolics are bioavailable as a wide range of metabolites with 
absorption occurring both in the small intestine and then in the large intestine within a few 




Analysis of the utilized oat bran detected nine phenolic acids amounting to 434 µg/g and three 
avenanthramides amounting to 41 µg/g (Table 1). These levels are comparable to four previous 
studies that analyzed wholegrain oats or oat bran, identifying up to 10 phenolic acids at levels 
ranging from 273 to 874 µg/g and three avenanthramides at levels ranging from 13 to 116 µg/g 
[9, 21-23]. The relatively wide range in the reported contents and compositions of phenolics 
can be explained by the different oat products analyzed (i.e. commercial or non-commercial 
varieties, bran or wholegrain, and hulled or de-hulled), and by the different extraction and 
analytical methods used for their analysis. Although other cereals may be richer sources of 
phenolic compounds (for example, Mattila et al. found 6.8-fold and 6.3-fold more total 
phenolic compounds in wheat and rye bran, respectively, than in oat bran [22]), oats are 
particularly interesting because of the relatively high proportions of phenolics in free and 
conjugated forms (24% in our oat bran and from 34 to 62% in non-commercial hulled 
wholegrain oats [9], whereas wheat has less than 18% [20]) and thus phenolic components 
from oats may have a higher bio-accessibility in comparison to other cereals. 
We observed high background excretion of all 33 oat-derived phenolic compounds (Supporting 
Information Table 3; Figure 2), even though volunteers followed a 48h low-phenolic diet. A 
high background phenolic excretion has previously been described in the control groups of 
other studies of (poly)phenol bioavailability after following 2 [24] or 7d [25] low phenolic 
dietary restrictions. These phenolic compounds may originate from the relatively low amounts 
of phenolics consumed in white bread and pasta during the dietary restrictions [20] and from 
the metabolism of other dietary components such as aromatic amino acids [26]. Despite this 
high background excretion, our data indicate that intake of oat bran leads to urinary excretion 
of 33 phenolic acid compounds which peak early at 0-2h, and again later between 4-8h (Figure 
2). The early appearance of metabolites suggests that the absorption of free phenolics from the 
oat bran occurs in the upper gastrointestinal tract with esterified conjugates being hydrolyzed 
 
 
by esterase activity in the intestinal mucosa [27], followed by the transfer of free phenolics 
across the intestinal epithelium through passive diffusion or via transporters [28]. Although we 
hypothesized that phenolics in the bound fraction would appear late in the urine (> 12 h), due 
to a requirement for gut microbiota to cleave covalent linkages between phenolic and fiber, the 
second peak of excretion was complete by 8 h, suggesting that the release and absorption 
occurred more rapidly (Figure 2). This agrees with previous studies, showing that bound 
phenolics may reach the colon and undergo microbial fermentation within 4 hours of oat bran 
intake. Indeed, in fasted volunteers (which was true in our study) a mean mouth-to-cecum 
transit time can be as rapid as 2.3h [29] and in vitro fermentation of wheat bran with human 
microbiota shows that digestion by microbial esterase and xylanase starts within 2h resulting 
in most fiber-bound phenolics being released within 6h [30]. 
The urinary recovery of ingested phenolics was on average 23.6±4.9% in the first 8 h after the 
oat bran intake, relative to the control (Table 2). Previous non-controlled studies reported lower 
mean recoveries in 24h urine of 4 ± 1%, 8 ± 2% and 3 ± 1% following ingestion of phenolics 
in wholegrain wheat bread [10], aleurone-enriched wheat bread [10] or wheat bran cereals [18], 
respectively, but a higher mean recovery of 29 ± 4% following ingestion of phenolics in instant 
coffee [17]. This wide variation in phenolic bioavailability may partly be explained by 
differences in the bioaccessibility of phenolics within the food matrix. While phenolic acids in 
coffee are conjugated to quinic acids and are relatively water soluble [17], the oat bran used 
here had 24% soluble phenolic acids (Table 1) and wheat bran cereals only 9% [18]. However, 
such direct comparisons of recoveries between studies may be of limited value due to the non-
controlled design of previous studies [10, 17, 18], and differences in the methods used to 
analyze phenolic acids in the urine and food samples including the number of metabolites 
targeted with the LC-MS/MS methods. 
 
 
Possible pathways for the metabolism of 12 ingested oat phenolic compounds into the 33 
excreted urinary compounds based on metabolic pathways previously described in the literature 
[17, 24, 31, 32] are provided in Supporting Information Figure 1. Notably, the major excreted 
compounds are downstream in the metabolic pathways (Figure 3 and Supporting Information 
Figure 1) and therefore products of extensive metabolism by endogenous and colonic microbial 
enzymes. Free forms of vanillic and isovanillic acids were the highest and 7th most highly 
excreted phenolics, respectively being mainly in the late peak between 4-8h after oat bran 
intake (Figure 3) and at levels totaling more than the total amount of vanillic acid that was 
ingested (mean ± SEM recovery: 159.2 ± 53.8%; Table 2). These data suggest that whilst only 
a limited amount of vanillic acid is absorbed directly in the small intestine, a larger proportion 
is absorbed following release by fermentation by the colonic microbiota with previous studies 
suggesting that it originated partly from the metabolism of avenanthramides and 
hydroxycinnamic acids [24, 31, 33, 34]. Vanillic acid may be formed by β-oxidation of ferulic 
acid in the liver, and isovanillic acid from methylation of caffeic acid to isoferulic acid followed 
by liver β-oxidation (Supporting Information Figure 1) [24, 31, 33, 34]. 4-, 3- and 2-
hydroxyhippuric acids were also highly excreted, with their excretion following a biphasic 
pattern (early 0-2h and late 4-8h) after oat bran intake (Figure 3). While hydroxyhippuric acids 
are common flavonoid metabolites detected, for example, following intake of orange juice [35] 
and cocoa [36], results from this oat trial and a recent wheat trial [10] suggest that 
hydroxyhippuric acids are also important metabolites derived from wholegrain. 
A study feeding 75-150mg avenanthramides in an oat extract detected nanomolar 
concentrations of circulating avenanthramides [11], while the present study detected only 
traces of the ingested 2.5mg avenanthramides in urine. This may suggest that avenanthramides 
are bioavailable when ingested at a relatively high dose and that avenanthramides are mostly 
metabolized particularly to hydroxycinnamic acids during their passage through the GI tract 
 
 
and into the circulation (Table 2). Hydroxycinnamic acids, in turn, undergo reduction, 
methylation, sulfation or glucuronidation, and are also metabolized to smaller hydroxybenzoic 
acids (Table 2, Supporting Information Figure 1). Chlorogenic acid and caffeic acid aglycones 
in coffee have a similar metabolic fate to avenanthramides and hydroxycinnamic acids in 
cereals. A study in ileostomy patients showed that although 33% of chlorogenic acid and 95% 
of caffeic acid were absorbed in the small intestine, only traces of chlorogenic acid and 11% 
of caffeic acid of the ingested dose were excreted in the urine [37]. The ingested 
avenanthramide dose given in the present study was only 2.5mg and this low dose may have 
prevented us from identifying avenanthramide metabolites. 
In conclusion, the present study showed that oat bran phenolics are bioavailable than previous 
studies reported [10, 17, 18] with 23.6±4.9% of the ingested dose being excreted in urine during 
8h following intake in the form of 33 different phenolics or their metabolites. The data showed 
that benzoic acid derivatives, and in particular (iso)vanillic acid, and three isoforms of 
hydroxyhippuric acids, accounted for a high proportion of the excreted compounds, together 
with ferulic acid sulfate. Future work is required to establish the detailed pharmacokinetics and 
circulating concentrations of these oat-derived phenolic compounds and to determine their 
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Figure 1: Study design overview 
Figure 2: Urinary excretion rate of total 33 oat-derived phenolic compounds after intake 
of 60g oat bran or a control meal in healthy men (µmol/h). Data are reported as mean ± SEM 
and were analyzed by two-factor repeated measurement linear mixed model with time and 
intervention as the two factors [significant effect of intervention (P = 0.004), time (P = 3*10-
13), and time and intervention interaction (P = 6*10-6)]. Post-hoc analysis with Tukey-Kramer 
adjustment was performed and P-values are indicated as follow: * P < 0.05; ** P <0.01; **** 
P<0.0001. 
Figure 3: Proportions of individual oat derived phenolics relative to total excretion levels 
at 0-2h, 4-6h and 6-8h. Excretion level differences between the oat and control interventions 
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Table 1: Content and composition of phenolics in 60g oat bran (mg and µmol)a) 
  
 Fraction 
  Conjugated and free Bound % Conjugated and free 
Avenanthramides    
Avenanthramide 2c 0.8mg (2.5µmol) ND 100% 
Avenanthramide 2f 1.0mg (3.1µmol) ND 100% 
Avenanthramide 2p 0.7mg (2.2µmol) ND 100% 
Hydroxycinnamic acids    
Ferulic acid 2.0mg (10.1µmol) 14.8mg (76.4µmol) 12% 
p-Coumaric acid 0.4mg (2.3µmol) 3.0mg (18.1µmol) 11% 
Caffeic acid 0.1mg (0.4µmol) 1.3mg (7.0µmol) 5% 
Sinapic acid 0.9mg (3.8µmol) 1.2mg (5.5µmol) 41% 
Hydroxybenzoic acids    
4-Hydroxybenzoic acid 0.2mg (1.8µmol) 0.3mg (1.9µmol) 48% 
Vanillic acid 0.4mg (2.4µmol) 0.4mg (2.2µmol) 53% 
Syringic acid 0.4mg (2.1µmol) 0.3mg (1.5µmol) 57% 
Benzaldehydes    
4-Hydroxybenzaldehyde 0.2mg (1.4µmol) 0.1mg (1.1µmol) 56% 
Vanillin ND 0.2mg (1.3µmol) 0% 
Total 7.0mg (32.1µmol) 21.6mg (115.0µmol) 24% 





Table 2: 0-8h absolute urinary excretion (µmol) of oat-derived phenolics and recovery of ingested dose (%) 
  Mean±SEM urinary excretion 0-8h (µmol)   Recovery of ingested dose (%)  
Excreted phenolics Control Oat bran Difference  Mean±SEM Lowest/highest absorber Oat parent compounds (Ingested dose) 
Avenanthramides        
Avenanthramide 2p 0.006±0.001 0.013±0.003 0.007±0.002   0.3 ± 0.1% 0.0% /0.7% Avenanthramide 2p (2.2µmol) 
Avenanthramide 2f 0.000±0.000 0.001±0.000 0.001±0.000  0.0 ± 0.0% 0.0% /0.1% Avenanthramide 2f (3.1µmol) 
Hydroxycinnamic acids        
Ferulic acid metabolitesa) 3.9±0.4 9.4±0.8 5.5±0.6  6.3 ± 0.7% 4.6% /8.5% Ferulic acid (86.5µmol) 
Caffeic acid-sulfate 0.4±0.2 1.2±0.4 0.8±0.5  10.7 ± 7% -15.4% /34.9% Caffeic acid (7.4µmol) 
Sinapic acid-sulfate 0.5±0.1 1.5±0.2 1±0.2  10.6 ± 1.6% 4.9% /15% Sinapic acid (9.3µmol) 
Hydroxybenzoic acids        
(Iso)vanillic acid 6.2±2.5 13.5±3.1 7.3±2.5  159.2 ± 53.8% -80.4% /308.3% Vanillic acid (4.6µmol) 
Benzoic acid-sulfate or -glucuronide 7.1±2 10.3±2.7 3.2±1  85.2 ± 26% 8.1% /176.1% 4-hydroxybenzoic acid (3.7µmol) 
Syringic acid-sulfate 0.4±0.1 0.9±0.2 0.5±0.1  14.6 ± 4% 1.5% /30.5% Syringic acid (3.6µmol) 
Total 33 phenolics 37.5±4.5 72.3±8.0 34.8±7.2   23.6 ± 4.9% 4.8% /41.6% Total 12 phenolics (147.1µmol) 


















Supporting Information Table 1 – Common and IUPAC names of phenolic compounds 
  
Common Name IUPAC Name 
List of available analytical standards 
2,4-dihydroxy benzoic acid 2,4-dihydroxybenzoic acid 
2,5-dihydroxy benzoic acid 2,5-dihydroxy benzoic acid 
2-hydroxyhippuric acid 2-[(2-hydroxybenzoyl)amino]acetic acid 
3-hydroxyhippuric acid 2-[(3-hydroxybenzoyl)amino]acetic acid 
4-hydroxybenzaldehyde 4-hydroxybenzaldehyde 
4-hydroxybenzoic acid 4-hydroxybenzoic acid 
4-hydroxyhippuric acid 2-[(4-hydroxybenzoyl)amino]acetic acid 
4-hydroxyphenylacetic acid 2-(4-hydroxyphenyl)acetic acid 
5-hydroxyanthranilic acid 2-amino-5-hydroxybenzoic acid 
Avenanthramide 2c 2-[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]amino]-5-hydroxybenzoic acid 
Avenanthramide 2f 5-hydroxy-2-[[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]amino]benzoic acid 
Avenanthramide 2p 5-hydroxy-2-[[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]amino]benzoic acid 
Caffeic acid (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid 
Dihydrocaffeic acid 3-(3,4-dihydroxyphenyl)propanoic acid 
Dihydroferulic acid 3-(4-hydroxy-3-methoxyphenyl)propanoic acid 
Dihydroferulic acid-4-O-glucuronide (2S,3S,4S,5R,6S)-6-[4-(2-carboxyethyl)-2-methoxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 
Dihydroxybenzoic acid-3-O-glucuronide (2S,3S,4S,5R,6S)-6-(5-carboxy-2-hydroxyphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid 
Ferulic acid (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid 
Ferulic acid-4-O-glucuronide (2S,3S,4S,5R,6S)-6-[4-[(E)-2-carboxyethenyl]-2-methoxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 
Gallic acid 3,4,5-trihydroxybenzoic acid 
Hippuric acid 2-benzamidoacetic acid 
Homovanillic acid 2-(4-hydroxy-3-methoxyphenyl)acetic acid 
Isoferulic acid (E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid 
Isoferulic acid-3-O-sulfate (E)-3-[3-sulfooxy-4-(methoxy)phenyl]prop-2-enoic acid 
Isovanillic acid 3-hydroxy-4-methoxybenzoic acid 
o-coumaric acid (E)-3-(2-hydroxyphenyl)prop-2-enoic acid 
p-coumaric acid (E)-3-(4-hydroxyphenyl)prop-2-enoic acid 
Protocatechuic acid 3,4-dihydroxybenzoic acid 
Salicylic acid 2-hydroxybenzoic acid 
Sinapic acid (E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoic acid 
Syringaldehyde 4-hydroxy-3,5-dimethoxybenzaldehyde 
Syringic acid 4-hydroxy-3,5-dimethoxybenzoic acid 
Vanillic acid 4-hydroxy-3-methoxybenzoic acid 
Vanillin 4-hydroxy-3-methoxybenzaldehyde 
Tentatively identified oat-derived phenolics 
 
 
3,4-dihydroxyhydrocinamic acid-glucuronide (2S,3S,4R,5R,6S)-3-(5-(2-carboxyethyl)-2-hydroxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
4-hydroxyphenylacetic acid-glucuronide (2S,4R,5R,6S)-3-(4-(carboxymethyl)phenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Benzoic acid-glucuronide (2S,3S,4R,5R,6S)-3-(4-carboxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Benzoic acid-sulfate 4-carboxyphenyl sulfate 
Caffeic acid-sulfate (E)-4-(2-carboxyvinyl)-2-hydroxyphenyl sulfate 
Dihydroferulic acid-glucuronide (2S,3S,4R,5R,6S)-3-(4-(2-carboxyethyl)-2-methoxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Dihydroxybenzoic acid-sulfate 4-carboxy-2-hydroxyphenyl sulfate 
Feruloylglycine 2-[[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]amino]acetic acid 
Homovanillic acid-glucuronide (2S,3S,4S,5R)-6-(4-(carboxymethyl)-2-methoxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Hydroxyhippuric acid-glucuronide (2S,3S,4R,5R,6S)-3-(4-((carboxymethyl)carbamoyl)phenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Hydroxyphenylacetic acid-sulfate 4-(carboxymethyl)phenyl sulfate 
(Iso)ferulic acid-glucuronide (2S,3S,4R,5R,6S)-3-(4-((E)-2-carboxyvinyl)-2-methoxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
(Iso)ferulic acid-sulfate 4-(2-carboxyethyl)-2-methoxyphenyl sulfate 
Sinapic acid-sulfate (E)-4-(2-carboxyvinyl)-2,6-dimethoxyphenyl sulfate 
Syringaldehyde-glucuronide (2S,3S,4R,5R,6S)-3-(4-formyl-2,6-dimethoxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Syringaldehyde-sulfate 4-formyl-2-hydroxy-6-methoxyphenyl sulfate 
Syringic acid-sulfate 4-carboxy-2,6-dimethoxyphenyl sulfate 
Vanillin-glucuronide (2S,3S,4R,5R,6S)-3-(4-formyl-2-methoxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 





Supporting Information Table 2 – sMRM transitions, parameters and detection limits of 33 identified oat phenolics and hippuric acid 
       
Metabolite RT MW sMRM ion transitions (m/z) Collision energy (V) LOD (nM) R2 
Aglycones       
2,5-dihydroxybenzoic acid 4.8 154.1 153 / 109 -11 4.7 0.999 
2,4-dihydroxybenzoic acid 5.5 154.1 153 / 109 -11 7.3 0.999 
Vanillic acid 5.6 168.2 169 / 93 12 9.8 0.994 
Isovanillic acid 6.0 168.2 169 / 93 12 7.3 0.999 
Syringic acid 6.5 198.2 197 / 182 -13 14.9 0.999 
Dihydroferulic acid 7.1 196.2 195 / 136 -15 21.5 1.000 
p-Coumaric acid 7.3 164.2 163 / 119 -13 4.2 0.997 
Ferulic acid 7.7 194.2 193 / 178 -10 8.2 1.000 
Salicylic acid 7.8 138.1 137 / 93 -23 4.2 0.999 
Avenanthramide 2p 9.9 299.3 298 / 254 -17 0.8 0.994 
Avenanthramide 2f 10.1 329 328 / 268 -24 0.6 0.990 
Glycines       
4-hydroxyhippuric acid 4.4 195.2 194 / 100 -11 4.3 0.997 
3-hydroxyhippuric acid 4.7 195.2 194 / 100 -11 24.5 0.999 
Hippuric acida) 5.7 179.2 178 / 134 -11 24.1 0.995 
2-hydroxyhippuric acid 7.0 195.2 194 / 100 -11 2.9 0.998 
Feruloylglycine 6.4 251.2 250 / 100*, 206, 191, 177, 149 -11 2.2 no standard 
Glucuronides       
Syringaldehyde OR Homovanillic acid OR  
3,4-dihydroxyhydrocinamic acid-glucuronideb,c) 4.2 358.2 357 / 113* , 59 , 137 , 175 , 181 -17, -23, -23, -11, -17 20.7 no standard 
Hydroxyhippuric acid-glucuronideb) 4.8 371.2 370 / 194* , 93 , 100 , 150 , 175 , 113 -11, -23, -11, -17 21.4 no standard 
Benzoic acid-glucuronideb) 5.1 314 313 / 113* , 175 , 137 , 93 -17, -17, -17, -23 15.7 no standard 
Ferulic Acid-4-O-Glucuronide 5.3  370.3 369 / 193* , 178 , 113 , 175 -19, -23, -19, -10 21.4 0.997 
Vanillin OR 4-hydroxyphenylacetic acid-glucuronideb,c) 5.3 328.1 327 / 113* , 107 , 175 , 151 -17, -23, -11, -11 35.0 no standard 
Dihydroferulic acid-4-O-glucuronide 5.8 372.3 371 / 113* , 195 , 85 , 175 -17, -20, -23, -17 11.7 0.990 
Isoferulic acid-glucuronideb) 6.1 370 369 / 193* , 178 , 113 , 175 -19, -23, -19, -10 11.2 no standard 
Dihydroferulic acid-glucuronideb) 6.2 372.3 371 / 113* , 195 , 85 , 175 -17, -20, -23, -17 8.0 no standard 
Sulfates       
Dihydroxybenzoic acid-sulfateb) 3.0 234 233 / 109* , 189, 153, 97 -23, -11, -23, -23 3.6 no standard 
Benzoic acid-sulfateb) 3.3 218 217 / 137*, 173 -11, -11 5.7 no standard 
Syringaldehyde-sulfateb) 4.1 262.2 261 / 166* , 123 , 181 -23, -23, -11 3.1 no standard 
Syringic acid-sulfateb) 4.1 278.2 277 / 197* , 182 , 153 , 123 -11, -23, -23, -23 2.6 no standard 
Caffeic acid-sulfateb) 5.4 260.2 259 / 179* , 135 , 107 -17, -23, -23 7.7 no standard 
Sinapic acid-sulfateb) 5.6 304.2 303 / 223* , 208 , 164 , 120 -11, -23, -23, -23 1.6 no standard 
(Iso)ferulic acid-sulfateb) 5.7 274.2 273 / 178* , 192 , 134 -20, -16, -25 1.6 no standard 
(Iso)ferulic acid-sulfateb) 5.9 274.2 273 / 178* , 192 , 134 -20, -16, -25 1.5 no standard 
Isoferulic acid 3-O-sulfate 6.1 274.2 273 / 178* , 192 , 134 -20, -16, -25 1.4 1.000 
Vanillin or hydroxyphenylacetic acid-sulfateb) 6.4 232.1 231.1 / 151*, 136, 92 -17, -23, -23 2.7 no standard 
*sMRM transition used for quantification; a)Hippuric acid, a common urinary excretion compound, was not identified as an oat-derived metabolite; b) site of conjugation could not be 
ascertained as identification was based on known transitions where pure standards for isomers were not available or separation of isomers was chromatographically not possible; c)tentatively 
identified compound which could have different isomeric configuration. Abbreviations: LOD, limit of detection (Signal/Noise = 3); MW, molecular weight; RT, Retention time; sMRM, 




Supporting Information Table 3 – Urinary excretion rate per hour of oat-derived phenolic compounds after intake of 60g oat bran or a 
control meal in six healthy men (nmol/h) 
              
             Model P value 





  µmol/h    
Avenanthramide A Oat 1±0  2±1** 1±0  2±0* 2±0  1±0  1±0  2±0  1±0  1±0  1±0  *** ** ** 
 CON 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0 1±0    
Aventhramide B Oat 0±0  0.3±0  0.3±0.1  0.2±0** 0.1 0 ND  ND  ND  0.1 ND  ** ** * 
 CON 0±0 0 ND ND ND ND ND ND ND ND 0.1    
Ferulic acid Oat 9±4 51±16 25±7 21±3 41±9 15±5 15±8 15±3 20±8 10±4 13±3 0.37 **** 0.06 
 CON 7±1 21±4 13±4 18±6 48±23 25±13 24±13 14±3 26±5 23±9 8±3    
p-coumaric acid Oat 1±0  6±2* 3±0  3±1  5±0  2±1  1±0  2±1  2±0  2±1  1±0  * *** * 
 CON 2±1 3±1 2±1 2±0 3±0 3±2 2±1 1±0 2±0 2±1 1±0    
Dihydroferulic acid Oat 29±15  90±42  25±9  60±17  378±135**** 109±68  35±17  23±5  78±22  50±19  23±6  0.07 **** *** 
 CON 11±4 56±28 26±8 17±10 87±34 38±24 32±10 24±5 101±66 84±55 18±5    
Isovanillic acid Oat 2±2  13±11  23±12  69±18  744±470**** 54±51  14±12  9±4  157±115  54±44  16±10  0.05 ** * 
 CON 4±4 9±9 9±7 62±14 87±39 3±1 1±0 1±0 59±17 4±1 1±0    
Syringic acid Oat 5±2  29±5  12±3  18±5  55±19**** 17±9  6±2  12±2  14±3  7±3  6±1  * **** *** 
 CON 2±1 13±3 12±3 8±2 16±3 7±2 8±1 19±7 14±3 13±4 4±1    
Salicylic acid Oat 67±59 171±64 143±54 64±22 222±120 31±16 17±5 95±66 103±36 109±82 30±14 ** 0.05 0.21 
 CON 6±2 14±6 39±17 32±12 43±7 24±11 11±5 20±9 22±8 24±8 9±3    
2,4-dihydroxybenzoic acid Oat 4±1  15±1  10±3  54±26* 62±18*** 13±5  19±13  10±2  36±19  8±3  8±2  ** ** *** 
 CON 4±1 11±3 14±5 6±2 11±4 6±2 5±2 18±8 5±2 6±2 4±2    
2,5-dihydroxybenzoic acid Oat 51±17  209±58*** 65±15  87±15  97±13  41±11  27±9  32±10  23±6  17±6  27±11  0.29 **** * 
 CON 47±9 73±24 70±24 53±20 73±15 34±11 29±16 40±24 27±16 43±31 20±8    
Vanillic acid Oat 29±14  175±36  67±14  3352±743** 2918±624* 201±98  48±21  39±12  1600±600  168±71  56±21  * **** * 
 CON 10±7 9±5 41±14 1281±624 1594±702 45±33 13±9 23±7 1162±513 128±37 25±17    
Hippuric acid Oat 2772±703 9454±2193 7027±2028 7653±2036 12773±1494 5060±2449 4158±1001 5857±1432 6817±1545 5006±1627 4930±683 0.12 **** 0.36 
 CON 2403±339 5052±1396 7131±1944 5439±1199 10688±1668 4905±592 3905±1209 3593±1437 6311±2403 6525±1869 2696±853    
2-hydroxyhippuric acid Oat 111±35  371±173* 133±35  245±104  525±82*** 182±74  137±28  198±107  133±37  81±21  117±27  ** **** ** 
 CON 101±21 113±29 121±32 84±17 195±20 101±21 58±23 54±20 99±41 158±55 58±20    
3-hydroxyhippuric acid Oat 443±148  1724±557** 958±278  1142±409  1643±302  332±126  452±98  599±209  650±329  288±75  557±98  * **** ** 
 CON 395±89 617±203 729±226 405±140 981±271 364±97 451±259 344±223 248±103 820±325 355±126    
4-hydroxyhippuric acid Oat 553±133  2262±551*** 1289±289  1566±457  2479±79  939±348  748±187  1108±274  1302±298  885±228  899±105  0.11 **** ** 
 CON 430±71 809±232 1133±342 807±195 1875±246 820±105 628±221 650±247 1020±334 1314±307 528±167    
Feruloylglycine Oat 11±5  32±12  11±2  28±8  56±18** 18±9  11±3  8±2  15±5  11±4  12±3  0.11 **** ** 
 CON 9±3 12±3 9±3 8±1 24±6 14±3 14±4 9±3 19±5 28±10 7±2    
Caffeic acid-sulfate Oat 68±31  298±127*** 90±38  128±41  87±26  23±10  18±7  11±4  24±12  14±5  12±4  0.64 0.06 *** 
 CON 65±27 28±8 13±4 30±12 137±98 110±84 47±19 18±6 76±51 103±62 22±9    
Syringaldehyde OR 





 CON 12±3 17±3 29±8 20±3 40±11 15±2 13±2 18±4 32±9 27±9 9±1    
(Iso)ferulic acid-sulfate Oat 78±25  879±142**** 560±104  474±57  661±119  245±82  101±36  170±39  359±76  219±71  118±29  **** **** **** 
 CON 48±14 71±20 282±63 210±51 454±87 135±31 79±22 121±54 235±74 131±58 70±25    
(Iso)ferulic acid-sulfate Oat 6±1  43±7**** 29±8** 20±4  28±6  12±5  7±2  8±1  16±3  10±3  7±1  ** **** **** 
 CON 5±2 5±1 13±3 9±1 25±4 9±2 6±1 7±2 15±4 14±4 5±1    
Isoferulic acid-3-O-sulfate Oat 2±0  23±3**** 16±5  12±1  7±1  11±6  3±1  1±0  4±1  4±2  3±2  0.12 *** **** 
 CON 1±0 3±1 9±4 6±2 12±7 4±2 2±1 6±3 7±4 6±3 3±1    
Syringic acid-sulfate Oat 19±8  99±20*** 54±9  51±10  165±54**** 76±29  27±10  41±8  47±9  32±7  23±4  ** **** **** 
 CON 15±6 22±9 58±15 20±4 68±16 26±9 22±8 35±12 51±16 52±16 13±3    
Sinapic acid-sulfate Oat 40±15  249±55**** 108±14  144±21  252±75** 66±23  51±17  55±13  103±20  49±11  34±6  ** **** **** 
 CON 28±15 31±13 59±12 41±8 130±17 57±25 45±15 40±11 101±33 78±27 32±10    
Dihydroxybenzoic acid-sulfate Oat 24±6  53±13* 27±7  51±12*** 35±7  16±4  18±6  16±1  18±4  18±5  25±4  0.22 0.07 **** 
 CON 16±5 18±2 14±5 9±2 28±6 23±8 26±8 11±2 18±6 37±18 17±6    
Benzoic acid-sulfate Oat 596±209  1697±494  720±219  1230±451  1283±274  1062±359  863±351  1034±274  1125±368  580±236  852±270  0.49 * * 
 CON 506±194 842±251 935±446 668±213 988±207 707±162 819±149 1073±295 1146±444 1066±464 461±143    
Vanillin or 
hydroxyphenylacetic acid-
sulfate Oat 13±9  81±50*** 19±11  40±23  29±15  12±7  12±5  20±11  13±6  9±3  9±3  0.27 * * 
 CON 4±1 11±7 6±3 6±3 9±4 6±3 7±3 9±5 7±3 6±2 7±4    
Ferulic Acid-4-O-Glucuronide Oat 49±20  221±69**** 171±45  170±27  214±33  62±23  61±22  57±14  128±30  67±26  52±11  **** **** **** 
 CON 45±12 44±10 85±20 67±12 171±21 75±19 58±9 45±16 123±25 101±40 38±8    
Isoferulic acid-glucuronide Oat 22±6  142±34**** 94±29  78±14  104±23  36±32  23±5  29±7  58±11  43±15  25±4  * **** ** 
 CON 17±4 21±5 39±9 29±5 67±8 33±6 20±3 20±6 57±7 41±9 15±4    
Dihydroferulic acid-4-O-
glucuronide Oat 3±1  11±4  9±2  16±5  49±22**** 21±10  7±4  7±3  9±2  10±3  8±3  ** *** ** 
 CON 3±1 5±2 5±1 6±2 13±5 7±4 5±2 5±1 8±5 13±8 7±2    
Dihydro(iso)ferulic acid-
glucuronide Oat 31±10  54±17  18±5  73±20  189±64**** 69±30  42±12  29±8  45±10  53±13  36±9  0.05 **** ** 
 CON 27±8 29±6 14±3 14±5 68±25 46±15 35±7 21±4 39±18 92±44 27±12    
Benzoic acid-glucuornide Oat 23±8  83±26  28±5  45±15  78±15** 36±11  34±7  37±14  29±6  16±4  23±5  *** **** * 
 CON 27±8 43±10 31±7 22±4 36±5 19±3 23±5 24±9 21±5 30±12 19±9    
Syringaldehyde OR 
Homovanillic acid OR 3,4-
dihydroxyhydrocinamic acid-
glucuronide Oat 128±30  440±148* 172±45  176±53  273±67  155±31  139±37  267±60  142±40  179±47  203±29  0.87 *** ** 
 CON 68±27 201±66 208±61 95±15 203±40 141±37 177±34 179±37 109±34 211±46 131±32    
Vanillin OR 4-
hydroxyphenylacetic acid-
glucuronide Oat 12±6  39±16  32±14 134±36**** 212±27**** 60±22  26±8  19±3  19±5  16±3  14±3  **** **** **** 
 CON 10±6 14±6 12±8 9±3 28±7 15±2 17±2 12±2 11±4 20±4 11±4    
Hippuric acid-glucuronide Oat 2±1  7±1  7±0  17±4  25±4**** 6±3  3±1  3±0  3±1  2±1  2±1  ** 0.08 ** 
 CON 1±0 4±1 2±1 2±0 4±0 3±1 2±0 2±1 4±1 2±0 2±0    
Hydroxyhippuric acid-
glucuronide Oat 5224±1199  18942±3806* 11925±2840  16455±3736  25747±2324  8914±3675  7106±1750  9827±1978  13065±2602  7912±2179  8162±1049  * **** * 
 CON 4343±586 8219±1978 11163±3008 9471±1769 18227±2049 6999±998 6562±1753 6417±2263 11065±3732 11217±3195 4619±1259    
 
 
Data are reported as mean ± SEM and were analysed by two-factor repeated measurement linear mixed model with time and treatment as the two factors. When the interaction effect was 
significant, post-hoc analyses with Tukey-Kramer adjustment were performed. If excretion was ND, the concentration was replaced with the limit of detection for statistical analysis. 
Model P values in the three far right columns and post-hoc P values next to the excretion rates are indicated as follow: * P < 0.05; ** P <0.01; *** P<0.001; **** P<0.0001. ND; not 






Supporting Information Figure 1 – Possible metabolic pathways on how the 12 ingested oat phenolic compounds are metabolized into 33 
excreted urinary compounds. The 5 top metabolites are highlighted with a blue background. COMT, catechol-O-methyl transferase, β-Ox, β-
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